{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:06:58Z","timestamp":1778843218363,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104744","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:20:45Z","timestamp":1771978845000},"page":"104744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+\/HER2\u2212 bone-only metastatic breast cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Adam","family":"Brufsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M.","family":"Layman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"McRoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Estevez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104744_bib1","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104744_bib3","article-title":"FDA approves abemaciclib for HR-positive","year":"2017","journal-title":"HER2-negative breast cancer"},{"key":"10.1016\/j.breast.2026.104744_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104744_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines(R) insights: Breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.breast.2026.104744_bib6","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.3390\/cancers15215268","article-title":"Palbociclib combined with an aromatase inhibitor in patients with breast cancer with lung or liver metastases in US clinical practice","volume":"15","author":"Brufsky","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104744_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1237751","article-title":"Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older","volume":"13","author":"Brufsky","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/oncolo\/oyae273","article-title":"Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness","volume":"29","author":"Brufsky","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104744_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.breast.2026.104744_bib10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/oncolo\/oyad209","article-title":"Real-world effectiveness of palbociclib plus aromatase inhibitors in African American patients with metastatic breast cancer","volume":"28","author":"Rugo","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104744_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.breast.2023.03.015","article-title":"Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer","volume":"69","author":"Rugo","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104744_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-024-01902-w","article-title":"Disparities in receipt of 1-(st) line CDK4\/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting","volume":"26","author":"Pilehvari","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104744_bib13","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104744_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-6-179","article-title":"Clinical management of women with metastatic breast cancer: a descriptive study according to age group","volume":"6","author":"Manders","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104744_bib15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/CMAR.S369910","article-title":"Clinical characteristics, prognostic factors and treatment outcomes of patients with bone-only metastatic breast cancer","volume":"14","author":"Marie","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.breast.2026.104744_bib16","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2022-12-2","article-title":"HR(+)\/HER2(-) de novo metastatic breast cancer: a true peculiar entity?","volume":"12","author":"Torrisi","year":"2023","journal-title":"Drugs Context"},{"key":"10.1016\/j.breast.2026.104744_bib17","doi-asserted-by":"crossref","first-page":"27990","DOI":"10.18632\/oncotarget.15856","article-title":"Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2026.104744_bib18","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/1759-7714.15452","article-title":"Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy","volume":"15","author":"Ji","year":"2024","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.breast.2026.104744_bib19","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.7150\/jca.26825","article-title":"Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis","volume":"9","author":"Kono","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.breast.2026.104744_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4143\/crt.2011.43.2.89","article-title":"Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer","volume":"43","author":"Lee","year":"2011","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104744_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0002-9343(86)90286-X","article-title":"Metastatic breast cancer confined to the skeletal system. An indolent disease","volume":"81","author":"Sherry","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.breast.2026.104744_bib22","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.3747\/co.25.4000","article-title":"Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines","volume":"25","author":"Matutino","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920987657","article-title":"Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program","volume":"13","author":"Bertho","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102308","article-title":"Measuring quality of life using patient-reported outcomes in real-world metastatic breast cancer patients: the need for a standardized approach","volume":"13","author":"Clarijs","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104744_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.11.004","article-title":"Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries","volume":"11","author":"von Moos","year":"2018","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111661","article-title":"Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4\/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials","volume":"11","author":"Rossi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104744_bib27","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1016\/j.clbc.2019.06.011","article-title":"First-line treatment for endocrine-sensitive bone-only metastatic breast cancer: systematic review and meta-analysis","volume":"19","author":"Toss","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104744_bib28","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104744_bib29","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"Monarch 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib31","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104744_bib32","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104744_bib33","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1200\/JCO.2017.74.6917","article-title":"US Food and drug administration pooled analysis to assess the impact of bone-only metastatic breast cancer on clinical trial outcomes and radiographic assessments","volume":"36","author":"Wedam","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice","volume":"23","author":"DeMichele","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104744_bib36","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.breast.2026.104744_bib37","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res"},{"key":"10.1016\/j.breast.2026.104744_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ijc.34748","article-title":"Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database","volume":"154","author":"Rugo","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104744_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000107772","article-title":"Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study","volume":"71","author":"Cazzaniga","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.breast.2026.104744_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05782-4","article-title":"Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials","volume":"184","author":"Finn","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104744_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.breast.2021.12.015","article-title":"The emerging role of real-world data in advanced breast cancer therapy: recommendations for collaborative decision-making","volume":"61","author":"Cottu","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104744_bib43","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2217\/fon-2020-1264","article-title":"CDK4\/6 inhibitors in HR+\/HER2- advanced\/metastatic breast cancer: a systematic literature review of real-world evidence studies","volume":"17","author":"Harbeck","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11523-021-00826-1","article-title":"Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice","volume":"16","author":"Brufsky","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030696","article-title":"Quantitative assessment of treatment response in metastatic breast cancer patients by SPECT-CT bone imaging-getting closer to PET-CT","volume":"15","author":"Gherghe","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104744_bib46","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/annonc\/mdu558","article-title":"Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?","volume":"26","author":"Woolf","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104744_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/CCI.20.00125","article-title":"Comparisons of real-world time-to-event end points in oncology research","volume":"5","author":"Walker","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.breast.2026.104744_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092480","article-title":"CDK4\/6 inhibitors in hormone receptor-positive metastatic breast cancer: current practice and knowledge","volume":"12","author":"de Melo Gagliato","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.breast.2026.104744_bib49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4048\/jbc.2022.25.e34","article-title":"Time to chemotherapy for patients with estrogen receptor-positive breast cancer and cyclin-dependent kinase 4 and 6 inhibitor use","volume":"25","author":"Endo","year":"2022","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.breast.2026.104744_bib50","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"}],"updated-by":[{"DOI":"10.1016\/j.breast.2026.104782","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000}},{"DOI":"10.1016\/j.breast.2026.104782","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:56:15Z","timestamp":1777600575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"alternative-id":["S0960977626000548"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104744","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+\/HER2\u2212 bone-only metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104744"}}